These regulatory phenomena have important consequences in melanoma treatment, where either TRIM28 overexpression or TRIM17 knockout lowers BCL2A1 protein levels and restores melanoma cell susceptibility to B-Raf protooncogene and serine/threonine kinase (BRAF)-directed therapy [165]. The gene discussed is MARK2; the disease is melanoma.